FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APF	PROVAL						
OMB Number:	3235-0287						
Estimated average burden							
hours per response	e: 0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* CHEN JIN-LONG (Last) (First) (Midd 333 OYSTER POINT BOULEVARD)	NGI NGI 3. Da	Issuer Name and Ticker or Trading Symbol NGM BIOPHARMACEUTICALS INC NGM Include the symbol of the symbol							5. Relationship of Repo (Check all applicable) X Director X Officer (give tit below) Chief Sci		licable) tor er (give title /)	10% Owner			
(Street) SOUTH SAN FRANCISCO (City) (State) (Zip)	0		07/01/2020 4. If Amendment, Date of Original Filed (Month/Day/Year)							5. Indiv ine) X	Individual or Joint/Group Filing (Check Applicable ne)				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day		Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquir Disposed Of (D) (Instr. 8)				Securities Beneficially		Form: Direct	of Indirect				
						Code	v	Amount	(A) or (D)	Price	Trai		ction(s) 3 and 4)		(111301. 4)
Common Stock 07/01/2)20			S ⁽¹⁾		17,737	D	\$18.	79 ⁽²⁾	79 ⁽²⁾ 1,027,268		D	
Common Stock 07/01/2)20		S ⁽¹⁾		7,263	D	\$19	0.2 ⁽³⁾ 1,0		20,005	D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
Derivative Conversion Date Ex Security or Exercise (Month/Day/Year) if a	Conversion or Exercise (Month/Day/Year) Execution Date, if any (Month/Day/Year) Derivative		action (Instr.	of Deriv	r osed) r. 3, 4	Expiration (Month/Dailties red assed 3, 4		Exercisable and ion Date Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amount or Number of Title Shares		8. Price of Derivative Security (Instr. 5) Benefic Ownee Follow Report Transa (Instr. 4)		Owners Form: Direct (or Indir (I) (Inst	Beneficial Ownership ect (Instr. 4)

- $1. \ The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020.$
- 2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$18.105 to \$19.095. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range
- 3. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$19.10 to \$19.315. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

/s/ Jin-Long Chen

** Signature of Reporting Person

07/02/2020

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.